Organisation paid for research Program year 2025 Source: CMS Open Payments

Broome Oncology

Neither a doctor nor a teaching hospital

Research payments

$615,817

152 payments

Through program year 2025, Broome Oncology is reported as receiving $615,817 in research payments, across 152 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $89 1
2023 Research $54,152 6
2022 Research $109,729 8
2021 Research $170,941 18
2020 Research $37,903 27
2019 Research $243,002 92

Breakdown

Who paid Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $220,372 25 payments
  2. Novartis Pharmaceuticals Corporation $161,778 3 payments
  3. Merck Sharp & Dohme Corporation $152,076 8 payments
  4. Eisai Inc. $63,190 100 payments
  5. Incyte Corporation $7,177 3 payments
  6. Janssen Research & Development, LLC $6,920 10 payments
  7. AstraZeneca Pharmaceuticals LP $3,554 2 payments
  8. Celgene Corporation $750 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. An Open Label Multi Center Rollover Protocol for Patients Who Have Participated in A Novartis Sponsored Ribociclib Lee011 Study and Are Continuing to Benefit From Ribociclib As Single Agent Or in Combination With Other Investigational Treatments $161,778 3 payments
  2. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative HR,HER2- in locally recurrent inoperable or Metastatic Breast Cancer KEYNOTE-B49 $151,732 7 payments
  3. Phase IIIII 1L CRC NivoCT wpt segmentationrational combos $84,884 1 payment
  4. Phase III 1L NSCLC nivo ipi chemo vs chemo in PDL-1 all comers $75,222 4 payments
  5. A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma $63,190 100 payments
  6. Nivo Dose Frequency Optimization Lung Trial $22,520 1 payment
  7. Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations $6,920 10 payments
  8. Ph III registrational SCLC $6,833 2 payments
  9. SUSTAIN, event driven trial $5,614 1 payment
  10. Lung cancer molecular profiling and clinical outcomes in US oncology community practices. $4,785 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record